Delving into the Latest Updates on Biota Pharmaceuticals, Inc. /Antibiotics Assets/ with Synapse

概览

关联

1

项与 Biota Pharmaceuticals, Inc. /Antibiotics Assets/ 相关的药物

Enzaplatovir

靶点

RSV F protein

作用机制

呼吸道合胞病毒F蛋白抑制剂

在研机构-

原研机构

Aviragen Therapeutics

在研适应症-

非在研适应症

呼吸道合胞体病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

6

项与 Biota Pharmaceuticals, Inc. /Antibiotics Assets/ 相关的临床试验

NCT02668367 / Completed临床1期

A Sequential-Cohort, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers

This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.

开始日期2015-11-01

申办/合作机构

Biota Pharmaceuticals, Inc. /Antibiotics Assets/

NCT02558413 / Completed临床1期

A Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers

This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1 clinical trial to determine the safety and tolerability of BTA-C585 administered orally to healthy subjects.

开始日期2015-08-01

申办/合作机构

Biota Pharmaceuticals, Inc. /Antibiotics Assets/

EUCTR2014-001785-95-BG / Not yet recruiting临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection. - Phase 2 Asthma

开始日期2015-03-25

申办/合作机构

Biota Pharmaceuticals, Inc. /Antibiotics Assets/

100 项与 Biota Pharmaceuticals, Inc. /Antibiotics Assets/ 相关的临床结果

登录后查看更多信息

0 项与 Biota Pharmaceuticals, Inc. /Antibiotics Assets/ 相关的专利（医药）

登录后查看更多信息

100 项与 Biota Pharmaceuticals, Inc. /Antibiotics Assets/ 相关的药物交易

登录后查看更多信息

100 项与 Biota Pharmaceuticals, Inc. /Antibiotics Assets/ 相关的转化医学

登录后查看更多信息